A subsidiary of Huahai Pharmaceutical recently received the Drug Registration Certificate for Telmisartan and Hydrochlorothiazide Tablets approved and issued by the National Medical Products Administration. The drug is used to treat essential hypertension, and its approval for production as a Category 4 chemical drug is deemed equivalent to passing the consistency evaluation. In 2025, the domestic market sales amount was approximately 187 million yuan, and the company's R&D investment was about 5.73 million yuan. The approval of this product will further enrich the company's product line and enhance market competitiveness.
Zhejiang Huahai Pharmaceutical Co LtdSubsidiary received drug registration certificate for Telmisartan and Hydrochlorothiazide Tablets, enriching product line and enhancing competitiveness.